Form 4: Redmile Group Reports Acquisition of IGM Biosciences Stock

Redmile Group, a significant shareholder in IGM Biosciences, reports acquiring additional shares through restricted stock units.

Summary

• Redmile Group, LLC, and Jeremy Green reported changes in their beneficial ownership of IGM Biosciences, Inc. stock.
• The report indicates the acquisition of 1,734 shares of common stock on September 30, 2024, at a price of $0.00 per share.
• These shares were acquired as fully vested restricted stock units, representing a quarterly retainer payment to Michael Lee, a managing director of Redmile Group, for his service on IGM Biosciences' Board of Directors.
• Following the transaction, Redmile Group's beneficial ownership amounts to 3,081,800 shares.
• Jeremy Green, as the principal of Redmile, may also be deemed to beneficially own these securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock acquisition related to director compensation. The increased holding by Redmile Group could be seen as slightly positive, but it's not a major event.

Positives

• The acquisition of additional shares by a major shareholder could be interpreted as a sign of confidence in IGM Biosciences' future prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.

Related Party Transactions

• The transaction involves a retainer payment in common stock to Michael Lee, a managing director of Redmile Group, for his service as a member of the Board of Directors of IGM Biosciences.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders due to the increased holding by a major shareholder.

Key Dates